Abstract：
UNASSIGNED: To evaluate serum prolactin and macroprolactin levels in patients on long-term proton pump inhibitors therapy.
METHODS: The cross-sectional study was conducted from January 2018 to November 2019 after approval from the ethics review committee of the Commission on Science and Technology for Sustainable Development in the South University, Abbottabad, Pakistan. The study included patients from two gastroenterology outpatient clinics in the Khyber Pakhtunkhwa province using proton pump inhibitors for ≥3 months either alone or in combination with either histamine receptor antagonists or prokinetics. Blood samples were collected from each patient for hormonal screening. Data was analysed using SPSS 25.
RESULTS: Of the 166 patients, 101(60.8%) were females and 65(39.2%) were males. The overall mean age was 42.5±14.2 years, and the median serum prolactin level was 23.2ng/ml (interquartile range: 14.0-38.0ng/ml). There were 96(58%) patients with normoprolactinaemia and 70(42%) with hypreprolactinaemia. There were 19(11.4%) patients using combination therapy, while the rest were on proton pump inhibitors monotherapy. There was a significant increase in serum prolactin level with combination therapy compared to monotherapy (p=0.001). Patients having treatment duration 11-20 months (p=0.006) and >40 months (p=0.001) were at high risk of developing hyperprolactinaemia.
CONCLUSIONS: Long-term use of proton pump inhibitors could increase serum prolactin levels, and appropriate evaluation is essential for clinical management.
METHODS: The cross-sectional study was conducted from January 2018 to November 2019 after approval from the ethics review committee of the Commission on Science and Technology for Sustainable Development in the South University, Abbottabad, Pakistan. The study included patients from two gastroenterology outpatient clinics in the Khyber Pakhtunkhwa province using proton pump inhibitors for ≥3 months either alone or in combination with either histamine receptor antagonists or prokinetics. Blood samples were collected from each patient for hormonal screening. Data was analysed using SPSS 25.
RESULTS: Of the 166 patients, 101(60.8%) were females and 65(39.2%) were males. The overall mean age was 42.5±14.2 years, and the median serum prolactin level was 23.2ng/ml (interquartile range: 14.0-38.0ng/ml). There were 96(58%) patients with normoprolactinaemia and 70(42%) with hypreprolactinaemia. There were 19(11.4%) patients using combination therapy, while the rest were on proton pump inhibitors monotherapy. There was a significant increase in serum prolactin level with combination therapy compared to monotherapy (p=0.001). Patients having treatment duration 11-20 months (p=0.006) and >40 months (p=0.001) were at high risk of developing hyperprolactinaemia.
CONCLUSIONS: Long-term use of proton pump inhibitors could increase serum prolactin levels, and appropriate evaluation is essential for clinical management.
摘要：
■评估长期质子泵抑制剂治疗患者的血清催乳素和大催乳素水平。
方法：横断面研究于2018年1月至2019年11月在南方大学科学技术促进可持续发展委员会的伦理审查委员会批准后进行，阿伯塔巴德,巴基斯坦。该研究包括来自开伯尔-普赫图赫瓦省两个胃肠病门诊诊所的患者，这些患者单独使用或与组胺受体拮抗剂或促动力学联合使用质子泵抑制剂≥3个月。从每个患者收集血液样品用于激素筛选。数据采用SPSS25进行分析。
结果：在166名患者中，101（60.8％）为女性，65（39.2％）为男性。总体平均年龄为42.5±14.2岁，血清催乳素水平中位数为23.2ng/ml（四分位距：14.0-38.0ng/ml）。有96例（58％）患有正常泌乳素血症的患者和70例（42％）患有高泌乳素血症的患者。有19例（11.4%）患者使用联合治疗，其余均为质子泵抑制剂单药治疗。与单一疗法相比，联合疗法的血清催乳素水平显着增加（p=0.001）。治疗持续时间为11-20个月(p=0.006)和>40个月(p=0.001)的患者处于发展高催乳素血症的高风险中。
结论：长期使用质子泵抑制剂可增加血清催乳素水平，适当的评估对于临床管理至关重要。
方法：横断面研究于2018年1月至2019年11月在南方大学科学技术促进可持续发展委员会的伦理审查委员会批准后进行，阿伯塔巴德,巴基斯坦。该研究包括来自开伯尔-普赫图赫瓦省两个胃肠病门诊诊所的患者，这些患者单独使用或与组胺受体拮抗剂或促动力学联合使用质子泵抑制剂≥3个月。从每个患者收集血液样品用于激素筛选。数据采用SPSS25进行分析。
结果：在166名患者中，101（60.8％）为女性，65（39.2％）为男性。总体平均年龄为42.5±14.2岁，血清催乳素水平中位数为23.2ng/ml（四分位距：14.0-38.0ng/ml）。有96例（58％）患有正常泌乳素血症的患者和70例（42％）患有高泌乳素血症的患者。有19例（11.4%）患者使用联合治疗，其余均为质子泵抑制剂单药治疗。与单一疗法相比，联合疗法的血清催乳素水平显着增加（p=0.001）。治疗持续时间为11-20个月(p=0.006)和>40个月(p=0.001)的患者处于发展高催乳素血症的高风险中。
结论：长期使用质子泵抑制剂可增加血清催乳素水平，适当的评估对于临床管理至关重要。
